The Role of Recombination for the Coevolutionary Dynamics of HIV and the Immune Response

Rafal Mostowy1*, Roger D. Kouyos1, David Fouchet2, Sebastian Bonhoeffer1

1 Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland, 2 Biométrie et Biologie Évolutive, Université de Lyon, Villeurbanne, France

Abstract

The evolutionary implications of recombination in HIV remain not fully understood. A plausible effect could be an enhancement of immune escape from cytotoxic T lymphocytes (CTLs). In order to test this hypothesis, we constructed a population dynamic model of immune escape in HIV and examined the viral-immune dynamics with and without recombination. Our model shows that recombination (i) increases the genetic diversity of the viral population, (ii) accelerates the emergence of escape mutations with and without compensatory mutations, and (iii) accelerates the acquisition of immune escape mutations in the early stage of viral infection. We see a particularly strong impact of recombination in systems with broad, non-immunodominant CTL responses. Overall, our study argues for the importance of recombination in HIV in allowing the virus to adapt to changing selective pressures as imposed by the immune system and shows that the effect of recombination depends on the immunodominance pattern of effector T cell responses.

Introduction

Human immunodeficiency virus (HIV) frequently undergoes recombination [1–3]. The high recombination rate is the consequence of both a high switching rate of reverse transcriptase between the two viral RNA strands during proviral synthesis [4–7] as well as of the large fraction of infected cells that harbour more than one provirus [8–10] (see [1] for review). Thus, when two non-identical virions infect the same cell, RNA from two different viruses can be packaged into a new virion, and upon a subsequent infection, a crossover event between the two RNA strands can result in Érecombination of the genetic material (see Fig. 1A). The evolutionary implications of recombination have been, to some extent, addressed in the context of the evolution of anti-retroviral resistance in HIV [11–16]. However, the effect of recombination in HIV coevolutionary dynamics between the virus and the immune system resembles the so-called Red Queen dynamics where recombination has been shown to play an important role [27–29]. In such a scenario, parasites adapt to infect frequent host genotypes, which gives rare host genotypes a selective advantage. Under these conditions recombination can give the host an edge in the arms race with the parasite by decreasing the viral replicative capacity [23,24], although compensatory mutations which partially restore the fitness can emerge [25,26] (see also Fig. 1C). Thus, HIV can efficiently escape the selective pressure of the immune system.

The immune escape dynamics in HIV can generate an environment which is beneficial for recombination. When the immune system generates immune responses against frequent virus strains, a strong selective pressure arises which leads to the escape of the virus. The immune system in turn produces novel responses that can recognize the escape variants and lead to further escape. The resulting coevolutionary arms race between the virus and the immune system resembles the so-called Red Queen dynamics between hosts and parasites, where recombination has been shown to play an important role [27–29]. In such a scenario, parasites adapt to infect frequent host genotypes, which gives rare host genotypes a selective advantage. Under these conditions recombination can give the host an edge in the arms race with the parasite by rapidly generating resistant genotypes. Thus in terms of the classical Red Queen terminology, HIV plays the role of the “host” and the immune system plays the role of the “parasite”. Given the parallel between host-parasite coevolution and virus-immune-system dynamics, it is plausible that recombination may, under appropriate conditions, help the virus to escape from the immune system.

In this study, we examine the role of recombination for immune escape of HIV by using a population dynamic model of
HIV. We find that recombination accelerates the evolution of escape in the virus in the early stage of infection. We also find that the CTL hierarchy is of vital importance to viral/immune coevolution as well as viral recombination. In particular, we find that the immunodominance pattern of the CTL response strongly affects the mean number of escapes in the virus as well as the impact of recombination. Furthermore, we determine which parameters increase or decrease the impact of viral recombination on the immune escape, and discuss in which situations genetic shuffling could contribute to the viral immune escape as well as to adaptation of HIV to the host in general.

Methods

General construction of the model

Mathematical models have proved an excellent tool for studying complex viral dynamics in vivo [30,31] as well as investigating population genetic and dynamic consequences of recombination [32]. Thus, in order to examine the impact of recombination on the viral immune escape we consider a population dynamic model which is an extension of a standard HIV dynamics model [33–35]. The model mimics the interaction of HIV with the immune system by taking into account some basic properties of the coevolutionary dynamics between the virus and the immune system. The model can be expressed by the following set of ordinary differential equations:

\[
\frac{dT}{dt} = \lambda - \delta_T T - \sum_{i=1}^{\alpha} \beta_i T I_i \frac{\beta_i T I_i}{1 + T + \sum_{i=1}^{\alpha} I_i},
\]

\[
\frac{dI_i}{dt} = \frac{\beta_i T I_i}{1 + T + \sum_{i=1}^{\alpha} I_i} - \delta_i I_i - k I_i \sum_{a=1}^{n} x_{ia} E_a.
\]
\[
\frac{dE_i}{dt} = a + gE_i \sum_{i=1}^{m} I_i z_{ia} - \delta_i E_i - \delta E_i. \tag{1}
\]

Three populations of cells are considered: susceptible naive CD4+ T cells (\(T\)), infected CD4+ T cells (\(I\)), and effector CD8+ T cells or CTLs (\(E\)). Naïve target cells, \(T\), are produced at a constant rate \(\lambda\), and die at a rate \(\delta_T\). They can become infected by any of \(m\) distinct viral strains in the population. A naïve T cell infected by a virus strain \(i\) becomes an infected cell of type \(I_i\). The virus is assumed to be in quasi-steady state [36], which implies that free virus is, to a good approximation, proportional to the infected cells at all times. The transmission rate of an infected CD4+ cell of type \(I_i\) is then defined as \(\beta_i = \beta f_i\), where \(\beta\) denotes the transmission rate by cells infected with a wild-type strain and \(f_i\) denotes the relative reproductive fitness of the virus strain \(i\) (which implies that \(f_{ai} = 1\)).

An infected cell displays \(n\) distinct types of MHC:peptide complexes, all of which are recognized at the beginning of infection by effector cells (CTL of type \(E\)). Naïve CTLs and here we focus solely on those mutations that result in a higher fitness of the two loci and 1; see Fig. 1C). The fitness of a double mutation partially restores it (uniformly drawn from the distribution of dissociation rates; defines the immunodominance pattern of the response \(K_a\)). Likewise, the activation and production of the effector sub-population \(E_o\) is proportional to the viral sub-population recognized by this clone. The effectors \(E\) are produced at a constant rate \(\sigma\), are activated to proliferate at a maximal rate \(g\), and die at a rate \(\delta_E\).

The rates of new infections and CTL production are assumed to obey Michaelis-Menten dynamics, which generates a saturation effect in these terms similar to the Michaelis-Menten enzyme-substrate kinetics [34,37,38]. By dividing the standard mass-action term by the density of the cells that undergo such kinetics, one generates more realistic and less oscillatory population dynamics of virus/immune-system interactions. The terms describing target cell depletion and the increase of infected cells saturate as a function of the total of naive and infected CD4+ cells, reflecting the T cell density-dependence of the transmission rate \(\beta\) [34]. Likewise, the proliferation via activation of the CTLs saturates as a function of infected cells and effector cells reflecting a non-trivial CTL kinetics \(i\) vivo, including competition for antigen and saturation in killing [35,39,40]. The constant \(K_a\) is a dissociation parameter, which is an inverse of the measure of sensitivity (avidity; see below) of the effector T cell clone \(a\); low \(K_a\) corresponds to a sensitive clone, and high \(K_a\) corresponds to an insensitive clone. By varying the distribution of the parameter \(K_a\), the immunodominance of an effector response is altered. The

### Table 1. Assumed parameter values for HIV dynamics.

| Parameter                  | Assumed value                                      | Name & reference                                      |
|----------------------------|----------------------------------------------------|-------------------------------------------------------|
| \(\lambda\)                | 2 \times 10^7 cells/d                             | Daily production of CD4+ target cells [31,55]         |
| \(\delta_T\)               | 0.01 d^{-1}                                       | Natural death rate of naive CD4+ target cells [56,57] |
| \(\max(\beta_i - \delta_i)\) | 1.5 d^{-1}                                        | Initial replication rate of the viral population [58]; taken from SIV assays |
| \(k\)                      | \(k_{\text{max}}/E^{-1} \cdot \text{cell}^{-1} \cdot \text{d}^{-1}; k_{\text{max}} = 0.9 \text{d}^{-1}\) by default | Assumes maximal CTL kill rate at 0.9 d^{-1}, and otherwise ranged between 0.1 - 10 d^{-1} [40,59,60] |
| \(\delta_i\)               | 0.1 d^{-1}                                        | Death rate of virus-infected cells not due to the CTL killing; chosen such that the total HIV death rate is 1 d^{-1} by default [61] |
| \(\gamma\)                 | 1.0 d^{-1}                                        | Maximal proliferation rate of CD8+ cells [62]         |
| \(K_a\)                    | variable; rand(\(K_{\text{min}}, K_{\text{max}}\)) by default | Distribution of dissociation rates; defines the immunodominance pattern of the response |
| \(\delta_E\)               | 0.01 d^{-1}                                       | Death rate of CD8+ cells [63,64]                      |
| \(a/\delta_E\)             | \(10^7\) cells                                    | Number of CD8+ cells of type a in the absence of infection; chosen based on the assumption that CD8+ T cell clones increase > 1000 -fold upon stimulation [65] |
| \(\sigma\)                 | variable, 15 by default                           | Number of targeted epitopes [56,67]                   |
| \(f_{\min}\)               | variable, 0 by default                            | Minimal fitness due to single mutation [68]          |
| \(\mu\)                    | \(3 \times 10^{-5}\)                              | Virus mutation rate per locus [69]                    |
| \(\rho\)                   | variable; 3 by default                            | Mean number of crossovers per genome [1,70]           |
| \(p_{\text{lbs}}\)         | 0.1                                               | Percentage of doubly infected cells [9,71]            |

DOI:10.1371/journal.pone.0016052.t001
overview of parameters together with the assumed values is given in Table 1.

**Mutation and recombination**

Mutation and recombination are implemented as stochastic events and are executed at discrete time steps during the simulation. When new mutants and recombinants are generated, the ancestral viruses are removed from the population of infected cells, new strains are added, and the set of equations (2) is restructured accordingly. Importantly, both mutation and recombination do not alter the number of infected cells but only the genetic composition of the provirus population.

In order to perform mutation, we approximate the number of CD4+ cells infected with a single virus of type \( i \) between the time \( t \) and \( t+\Delta t \) as

\[
\Delta I_i(t) = \frac{\beta_i T(t) I_i(t)}{1 + T(t) + \sum k=1^{\infty} I_k(t)} \Delta t. \tag{2}
\]

This fraction undergoes mutation and is changed accordingly in the population. The mutation step is carried out by assuming that mutation occurs independently at every locus with probability \( \mu \).

In order to perform recombination, we assume at every time-point that (i) a fraction \( p_{db} \) of all infected cells is doubly infected, (ii) amongst these doubly infected cells, the cells infected with two different strains \( i \) and \( j \) occur at a frequency \( 2I_iI_j/\left(\sum_k I_k\right)^2 \), which implies that the infection of a target cell by one virus strain happens independently from infection of the same target cell by another virus strain, (iii) a cell doubly infected with virus strains \( i \) and \( j \) produces a new infection between the time \( t \) and \( t+\Delta t \) with the probability

\[
\frac{(\beta_i + \beta_j)/2}{1 + T(t) + \sum k=1^{\infty} I_k(t)} T(t) \Delta t, \tag{3}
\]

(iv) in the course of such infection event, strains \( i \) and \( j \) are enclosed in the same viral capsule with the probability of 50%, and that (v) the average number of crossover events is equal to \( \rho \) and crossover-sites are randomly distributed across the viral genome. Likewise, the newly recombined strains substitute the old strains in the population of infected cells.

**Measures**

**Escape types.** We distinguish between two types of escape, E and EC. The escape E is the escape which only carries a mutation at the escape locus and regardless of the type of allele at the compensatory locus; the escape EC is the escape which carries a mutation at both escape locus and the compensatory locus (see Fig. 1C). Unless mentioned which type of escape mutation is analyzed, we refer to the E escape type.

**Time of escape.** The average time of escape of a mutant with \( k \) escape mutations is measured by calculating the total abundance of CD4+ cells infected with viruses with \( k \) escape mutations and capturing the time when the number of these cells exceeds \( 10^5 \).

**Mean number of escapes.** The mean number of escape variants in the population at a given time is calculated by the mean Hamming distance of the escape types from the wild type. For example, in order to calculate the mean number of E escape variants, we calculate the abundance of all strains with the number of E escapes equal to zero, one, two, etc., then multiply each by its Hamming distance from the wild type, and finally weight by the total virus load.

**CTL avidity.** Each CTL clonal sub-population has its assigned sensitivity (avidity) value \( S_{cl} = \max(K_a)/K_p \), where \( K_a \) is the Michaelis-Menten constant assigned to each clone. Thus, the least sensitive population has mean avidity of 1. For each run (unless mentioned otherwise), we randomly choose the \( K_a \) values between \( K_{max} \) and \( K_{min} \).

**CTL diversity.** The diversity of the CTL population is a measure of their distribution. At each time point in one simulation run we calculated the diversity of the CTL response by the use of the Shannon diversity index \( 1 + (\sum c_i \log c_i)/\log(n) \) where \( c_i \) is a frequency of each CTL clone and \( n \) is the number of CTL clones. The mean diversity was calculated by first averaging over all simulations runs and then over time.

**Results**

The aim of this study was to examine the impact of recombination on the immune escape of HIV. To that end, we considered a deterministic, population dynamic model of HIV infection with a stochastic implementation of mutation and recombination [33–35], and examined the viral-immune dynamics with and without recombination (see Methods). Using the model we quantified the impact of recombination on a number of important characteristics of the viral population (viral load, emergence of escape, diversity, etc.) as well as a number of important characteristics of the immune system (strength, distribution of CTL clones, etc.).

Recombination accelerates the acquisition of escape mutations

A key question is whether recombination can accelerate the emergence of escape mutations in HIV, and if so, whether this is beneficial for the virus. Fig. 2 shows two representative simulation runs of the immune escape dynamics with and without recombination. The figure shows the frequencies of escape mutations at different epitope loci with three chosen escape frequencies shown in colour. Fig. 2A shows an example of dynamics where the impact of recombination is high. Fig. 2B shows an example of dynamics where the impact of recombination is low. This illustrates that recombination can, but does not generally accelerate the emergence and the fixation of immune escape. Furthermore, the distinct escape dynamics which can be seen in both panels suggest that the characteristics of the immune response play an important role in the scale of the recombination impact, as will become evident in the next section. (Even though the virus recombines with the same strength, the properties of not only the virus but also the immune system lead to a much weaker effect of recombination.)

In order to assess a general impact of recombination on the evolution of escape in HIV, we measured the mean time of appearance of escape mutations during infection. In particular, we measured an average speed of accumulation of successive mutations from the time point of infection, i.e. the average time of appearance of a single mutant, the average time of appearance of a double mutant, etc. The results are presented in Fig. 3 where panel A shows the average times of appearance of successive E escape mutants and panel B shows the average times of appearance of successive EC escape mutants (see Methods and Fig. 1C for an explanation of E and EC escape mutants).

The figure shows that in runs with recombination successive escape variants appear faster than in the runs without recombina-
tion, and that the accumulating effect of recombination increases with the number of escape mutations. The impact of recombination is even stronger for EC than for E escape types. Since EC escapes need two point mutations, the results suggest that genetic shuffling not only helps bringing together escape mutations from different epitopes but also bringing together escape and compensatory mutations at the same epitope (see Discussion). Thus, our model shows that recombination accelerates the emergence of escape variants by clustering together various escape mutations in the virus.

On the other hand, the acceleration of the emergence of escape mutations is likely to have other consequences on the virus dynamics, and thus we next examined which of the determinants of the viral population are significantly affected by genetic shuffling. We found that recombination has a considerable impact on viral diversity as well as the average number of escape mutations in the population. The results are shown in Fig. 4 where the average over many stochastic simulation runs is considered. Fig. 4A shows the viral genetic diversity as a function of time since the beginning of infection. One can see that due to the faster appearance of escape variants, a higher level of genetic diversity is achieved in virus populations with recombination. Fig. 4B shows the mean number of E escapes in the viral population as a function of time (see Methods). The runs with recombination resulted in an increased level of escape on the population scale early in the infection, however after 2–3 years the same runs (ρ > 0) showed only a marginally higher number of escapes than the runs without recombination.

Figure 2. Example simulation runs of the virus escape dynamics. Simulation runs without recombination are shown with solid lines, and with recombination with dashed lines. Plotted are frequencies of escapes at all $n = 15$ loci as a function of time, and in each case three chosen loci are printed in colour. Panel A shows an example simulation run for a parameter setting in which the impact of recombination is strong. Panel B shows an example simulation run for a parameter setting in which the impact of recombination is weak. Recombination mostly, but not always, accelerates the emergence and fixation of immune escapes. Parameters used in panel A: $f_{\min} = 0.6$, $K_{\min} = 0$, $K_{\max} = 10^9$, $\rho = 0$. Parameters used in panel B: $f_{\min} = 0.0$, $K_{\min} = 0$, $K_{\max} = 5 \times 10^8$, $\rho = 1$; the remaining parameters are the same and are defined in Table 1.

doi:10.1371/journal.pone.0016052.g002

Figure 3. The average times of appearance of successive accumulations of escape mutations. In both panels the time of emergence of mutants with a given number of escape mutations is shown. Orange and blue bars correspond to runs with and without recombination, respectively. A shows the time of appearance of E escapes (escapes at the escape locus). Panel B shows the time of appearance of EC escapes (escapes at the escape and compensatory locus). The simulations show that recombination accelerates the emergence of escape mutations. Parameters used: $f_{\min} = 0$, $K_{\min} = 0$, $K_{\max} = 10^9$; the others are defined in Table 1. The plot shows an average of 10000 simulation runs.

doi:10.1371/journal.pone.0016052.g003
recombination ($\rho = 0$). The initial increase in the number of escapes occurred because of a high selective pressure to escape the CTL responses, resulting in a subsequent decrease of the stimulation of T cells and hence of the selective pressure. At the same time, an increase in the mean number of escapes decreased the fitness of the virus population, making it susceptible to the invasion by strains with the wild-type allele (results not shown). As a result, the escape epitopes became selected against during the chronic stage of infection.

In line with this interpretation, we observed little or no reversion to the wild-type in simulations where the cost of escape was low or absent (results not shown). The higher mean number of escapes with $\rho > 0$ suggests that the process of selecting escape variants in the primary phase of infection was accelerated by the mechanism of recombination. Interestingly, we observed that recombination had no significant effect on the viral load unless the process of escape led to the appearance of an escape mutant with a substantially decreased kill rate and a relatively high replicative capacity (results not shown; see Discussion).

### CTL dynamics and the impact of recombination

Several measures of the T cell response are used extensively in immunological literature (e.g. immunodominance, breadth, strength). However, using them to characterize the CTL dynamics during a viral infection has the disadvantage that these measures not only result from the properties of the immune cells but are strongly affected by the interactions of the immune response with the virus and the stochastic effects. In order to characterize the response itself, one could measure the avidity distribution of the T cell population for a given antigen, but such quantification in experimental assays remains not feasible. A mathematical model, on the other hand, has the advantage that the sensitivity of each CD8+ T cell clone to the wild-type virus is defined before the simulation run (by the avidity value $\alpha_i$; see Methods). Therefore, in this study we propose to quantify the CTL response by the mean avidity and the variance of avidity in each run. In this way, (a) two independent variables are used to quantify the immune response, while typical measures used in the literature can be read off the plot, and (b) a correspondence between the measures of the T cell population and the observed immune dynamics are investigated.

The results are displayed in Fig. 5 where panel A shows the diversity of the CTL response as a function of mean and variance of the T cell avidity (see Methods) averaged over many simulations ($\rho = 0$ assumed but results for $\rho > 0$ are qualitatively the same). As expected, the diversity of the CTL response decreases (responses become more even) as the variance of avidity decreases (low diversity for low avidity occurs because all clones are equally weak). However, increasing the mean avidity at a constant variance (with the exception of the zero variance and the very weak response) increases the evenness and hence the breadth of the response. Thus we see that the relation between the avidity and the breadth of the response can be non-trivial and counter-intuitive.

Fig. 5B shows the mean number of escapes at the escape loci after one year from infection, as a function of the mean and the variance of avidity. Fig. 5C shows the factor of increase in the measure in panel B due to recombination. One can see that as the potency (mean avidity) of the immune response increases, the efficiency of escape reaches an optimum, namely an initial increase in the impact of recombination is followed by a decrease. The initial increase occurs because with a higher avidity the strength of the immune system increases and so does the selective pressure. However, as explained above, by increasing the mean avidity the hierarchy of the immune response changes yielding a broader CTL response. Such immune response effectively targets the virus at many loci, disabling the evasion of the immune system (escape becomes too costly). However, at the same time that the immune response broadens, the impact of recombination becomes stronger. This is particularly evident for potent and non-immunodominant CTL responses, i.e. for runs with high mean and small variance in avidity. We see qualitatively the same pattern when measuring the acceleration of the appearance of the full escape mutant (Fig. 5D–F).

Why is the impact of recombination stronger for broader (non-immunodominant) responses? The reason is that when all effector responses are similarly strong, the expected time of escape at any epitope will be comparable, meaning that all epitopes will escape...
on average at a similar time because they will all become advantageous at a similar time. A multiple number of escape variants increasing in frequency will in turn allow for almost any combination of those mutations to be advantageous too, possibly outgrowing variants with a smaller number of escape epitopes. This creates an environment in which genetic shuffling will have a

**Figure 5. CTL dynamics and the impact of recombination.** Figures are plotted as a function of mean avidity and variance of avidity of the CTL response. Panel A shows the mean diversity of the CTL population which decreases with increasing mean (except for an initial increase in avidity) and decreasing variance in avidity. Panel B shows the mean number of escapes during infection without recombination after 1 yr. of infection, which has an optimum for a given mean avidity of response and correlates well with the diversity of the CTL response in panel A. Panel C shows the factor of increase in the number of escapes after one year (cf. panel B) due to recombination, which is the strongest for broad and even responses. Panels D and E show the time of appearance (days) of the full escape variant without and with recombination, respectively. The hatched areas show runs in which the full escape mutant did not appear within the time of 1000 days. The impact of recombination on the time of emergence of the full escape mutant, shown in panel F, corresponds well to the impact of recombination on the number of escape mutations after one year, shown in panel C. The mean and variance of log avidities ($M$ and $V$, respectively) plotted in all panels are defined in each simulation, and the distribution of avidity values is drawn from a uniform distribution in each simulation run between $M - \sqrt{3}V$ and $M + \sqrt{3}V$. The parameters used: $f_{min} = 0$, $n = 10$, $\rho = 2$. All other parameters are given in Table 1. Each point in the plot shows an average of 5000 simulation runs. doi:10.1371/journal.pone.0016052.g005
Discussion

In this study we show that recombination in HIV accelerates the initial phase of viral coevolution with the immune system. We demonstrate that random shuffling of the genetic material (a) accelerates the emergence of escape mutations (both with and without compensatory mutations), (b) increases viral diversity during infection (in line with the experimental observations; see [41]), (c) accelerates the acquisition of escape mutations in the early stage of infection. Furthermore, our model exhibits a negative correlation between the impact of recombination and the efficiency of escaping the immune system. In particular, we observe that the impact of recombination is strongest in broad, non-immunodominant mutants. Although our analysis focuses on the escape from cytotoxic T-lymphocytes, similar effect might occur with escape from other virus-specific responses including antibodies.

Generally, we see a higher impact of recombination with than without compensatory mutations, suggesting an acceleration in the adaptation of the virus due to recombination in spite of positive epistasis (a double mutant has higher fitness than a single mutant). This may seem paradoxical as under positive epistasis, recombination may be expected to decelerate adaptation [42]. We see three potential explanations for this paradox: (i) stochastic effects in this model may override the effects of possible epistasis [11]; (ii) the epistasis experienced by the virus is also influenced by the CTL dynamics, and these could therefore outweigh the positive epistasis of compensatory mutations with respect to reproductive fitness; and (iii) more generally the model here is substantially more complex than the population genetic models that have been used to determine the mentioned effects of epistasis on recombination, such that it is difficult to translate their observation to the situation considered here.

Depending on the total fitness cost of escape, and thus also on the number of escape loci, a mutant can arise that escapes at all loci. Because such full escape is no longer controlled by the immune response, the appearance of this mutant is accompanied by a substantial increase in viral load. The time of appearance of the full escape mutant depends strongly on the recombination rate. However, whether such total escape ever occurs in late stage patients is currently unclear.

Generally, we find that viral recombination increases the set-point viral load. Given the moderate magnitude of this increase (typically 5–10%, data not shown) and the large variance seen between clinical measurements of the virus load, it is not an effect that could easily be detected in clinical data even if there were considerable variation in recombination rates between different viral isolates. The fact that in our model recombination has only a weak effect on virus load, however, is compatible with strong selective pressures on escape mutants, as observed experimentally [23,43–47], because large changes in viral fitness as such do not necessarily induce substantial changes in virus load [48,49].

As common strains are likely to be targeted more strongly by the immune response, a negative frequency dependent selection may ensue, leading to potentially cyclical frequency dynamics between the virus and the immune system. This behaviour shows a resemblance with the so-called Red Queen dynamics in evolutionary biology, where fluctuating selection in host-parasite systems leads to allele frequency cycles and the maintenance of genetic variants over long periods of time. One of the leading hypothesis for the evolution of recombination (Red Queen Hypothesis) states that such circumstances can explain the evolutionary maintenance of genetic shuffling [50–52] (see [29] for a review). Here, we have focused on examining the consequences rather than the evolution of recombination rate. Nevertheless, the fact that viral recombination accelerates the acquisition of beneficial mutations in the virus indicates that recombination, like in the Red Queen scenario, could be advantageous for the virus. However, our model differs in a number of ways from the typical Red Queen models (multiple loci, absence of persistent allele fluctuations, interaction models, etc.), and whether the observed benefit of recombination stems from the similar effects as in the Red Queen Hypothesis is a topic that warrants further investigation.

Although the primary aim of this study has been the impact of recombination on the coevolution of HIV with the immune system, the results presented here might shed light on the evolutionary history of recombination in HIV (or other retroviruses like SIV). On the one hand, we have found that recombination can have a strong impact on the speed of acquisition of escape mutations, and thus arguably, on the adaptation of the virus to the new hosts. This suggests that the within-host selection acting on the virus might select for non-zero recombination rates. On the other hand, the total viral load has been correlated with the transmission probability of HIV, and since we have seen that recombination moderately increases the total virus load, the between-host selection acting on the viral recombination is likely to be weak or zero. This also emphasizes the importance of the within-host stage of evolution of HIV. However, what evolutionary forces act on recombination and how, as well as whether HIV had enough time to evolve its recombination rate, remains a matter of discussion.

HIV and the immune system remain one of the best qualitatively and quantitatively characterized coevolutionary systems. However, a better insight into the coevolutionary dynamics underlying the interaction of the virus with the immune system, as well as into the population dynamical consequences of recombination, requires an improved understanding of the parameter space defining these interactions. First, the recently underlined importance of macrophages in the development of HIV infection [53] as well as of an increased recombination rate in those cells [54] suggests that the inclusion of macrophages in a model of recombination might qualitatively affect the outcome of this study. Second, we have seen a positive correlation between the number of crossover events in HIV and the mean number of escape mutants in the late stage of infection (results not shown). Therefore, a better understanding of the relation between viral
fitness in vivo and the number of escape mutations in the chronic phase of the infection might yield further insight into understanding the optimal recombination rate in HIV. Third, our results show that of particular importance is the estimation of the fitness of escape mutants in the context of the immune system (in vivo). This first component of the fitness in vivo reflects the interaction of the virus and the immune response. This is encapsulated by the parameter avidity, which describes both the activation of the immune response by the virus as well as its subsequent recognition and the killing by the immune system. Obtaining more quantitative data on the specificity and diversity of the T cell repertoire recognizing the virus would allow better understanding of the effect of recombination on the population dynamics of the virus, and more generally would enable more quantitative approaches to the causes underlying immunodominance.

Acknowledgments
We thank Viktoria Muller and Roland R. Regoes for careful reading of the manuscript. We also acknowledge Frederik Graw for helpful discussions concerning the CTL kinetics.

Author Contributions
Conceived and designed the experiments: RM RDK SB. Performed the experiments: RM. Analyzed the data: RM RDK DF SB. Contributed reagents/materials/analysis tools: SB. Wrote the paper: RM.

References

1. Onafuwa-Nuga A, Telesnitsky A (2009) The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microb Mol Biol Rev 73: 451–480.
2. Robertson DL, Sharp PM, McCutchan FE, Hahn BH (1995) Recombination in HIV-1. Nature 374: 124.
3. Wooley DP, Smith RA, Gazjka S, Desrosiers RC (1997) Direct demonstration of retroviral recombination in a rhesus monkey. J Virol 71: 9650.
4. An W, Telesnitsky A (2002) HIV-1 genetic recombination: experimental approaches and observations. AIDS Rev 4: 195–212.
5. Chen J, Powell D, Hu WS (2006) High frequency of genetic recombination is a common feature of primate lentivirus replication. J Virol 80: 9653–9658.
6. Kuwata T, Miyazaki Y, Igarashi T, Takehisa J, Hayami M (1997) The rapid spread of recombinants during a natural in vitro infection with two human immunodeficiency virus type 1 strains. J Virol 71: 7085–7091.
7. Rhodes T, Wargo H, Hu WS (2005) High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J Virol 77: 11193–11200.
8. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S et al. (1997) Evidence for positive episomal replication in human immunodeficiency virus type 1. J Virol 71: 11789–11800.
9. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S et al. (2003) High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J Virol 77: 11193–11200.
10. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S et al. (2003) High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J Virol 77: 11193–11200.
11. Althaus CL, Bonhoeffer S (2005) Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 79: 13572–13573.
12. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004) Antigenic Oscillations and Shifting Immunodominance in HIV-1 Infections. Nature 375: 606–611.
13. Bryant RV, Bryant MV, Bryant DS et al. (1963) Antigenic Oscillations and Shifting Immunodominance in HIV-1 Infections. Nature 375: 606–611.
14. Althaus CL, Bonhoeffer S (2005) Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 79: 13572–13573.
15. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004) Evidence for positive episomal replication in human immunodeficiency virus type 1. J Virol 71: 11789–11800.
16. Fraser C (2005) HIV recombination: what is the impact on antiretroviral therapy? J Res Soc Interface 2: 489.
17. Fraser C (2005) HIV recombination: what is the impact on antiretroviral therapy? J Res Soc Interface 2: 489.
18. Kousyos RD, Bouhoffer S (2009) Recombination and drug resistance in HIV-1. J Virol 83: 17589–17592.
19. Kousyos RD, Bouhoffer S (2009) Recombination and drug resistance in HIV-1. J Virol 83: 17589–17592.
20. Kousyos RD, Bouhoffer S (2009) Recombination and drug resistance in HIV-1. J Virol 83: 17589–17592.
21. Kousyos RD, Bouhoffer S (2009) Recombination and drug resistance in HIV-1. J Virol 83: 17589–17592.
22. Kousyos RD, Bouhoffer S (2009) Recombination and drug resistance in HIV-1. J Virol 83: 17589–17592.
23. Kousyos RD, Bouhoffer S (2009) Recombination and drug resistance in HIV-1. J Virol 83: 17589–17592.
46. Mandl JN, Regoes RR, Garber DA, Feinberg MB (2007) Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape. J Virol 81: 11982–11991.

47. O'Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, et al. (2004) A dominant role for CD8+ T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol 78: 14012–14022.

48. Bonhoeffer S, Coffin JM, Nowak MA (1997) Human immunodeficiency virus drug therapy and virus load. J Virol 71: 3275–3278.

49. Bonhoeffer S, Funk GA, Gounard HF, Fischer M, Muller V (2003) Glancing behind virus load variation in HIV-1 infection. TRENDS Microbiol 11: 499–504.

50. Bell G (1982) The Masterpiece of Nature: The Evolution and Genetics of Sexuality. Kluwer Academic Publishers.

51. Hamilton WD (1976) Gamblers since life began: barnacles, aphids, elms. Quart Rev Biol 51: 407–412.

52. Jaenike J (1978) An hypothesis to account for the maintenance of sex within populations. Evol Theory 3: 191–194.

53. Benaroch P, Billard E, Gaudin R, Schindler M, Jouve M (2010) HIV-1 assembly in macrophages. Retrovirology 7.

54. Levy DN, Aldrovandi GM, Kuch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Nat Acad Sci 101: 4204–4209.

55. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, et al. (1999) Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 5: 83–89.

56. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD (1998) Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279: 1223–1227.

57. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203: 285–301.

58. Petravic J, Ribeiro RM, Casimiro DR, Mattapallil JJ, Roederer M, et al. (2008) Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. J Virol 82: 11589–11598.

59. Asquith B, Mosley AJ, Barfield A, Marshall SF, Heaps A, et al. (2005) A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human immunodeficiency virus type 1 proviral load. J Gen Virol 86: 1515–1523.

60. Regoes RR, Barber DL, Ahmed R, Antia R (2007) Estimation of the rate of killing by cytotoxic T lymphocytes in vivo. Proc Nat Acad Sci 104: 1599–1603.

61. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037–5038.

62. Davenport MP, Ribeiro RM, Perelson AS (2004) Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol 78: 10096–10103.

63. Oggi GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, et al. (1999) Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy. J Virol 73: 797–800.

64. Casazza JP, Betts MR, Picker LJ, Koup RA (2001) Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 75: 6508–6516.

65. Butz EA, Bevan MJ (1998) Massive expansion of antigen-specific CD8 T cells during an acute virus infection. Immunity 8: 167–175.

66. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77: 2081–2092.

67. Wang YE, Li B, Carlson JM, Sreeck H, Gladden AD, et al. (2009) Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 83: 1845–1855.

68. Parera M, Fernandez G, Clotet B, Martinez MA (2007) HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol 24: 392.

69. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087–5094.

70. Juste AE, Yu H, Klaarmann GJ, Ron Y, Preston BD, et al. (2008) High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74: 1234–1240.

71. Jossefson L, Palmer S, Casazza J, Ambrozak D, Kearney M, et al. (2010) Analysis of hiv dna molecules in paired peripheral blood and lymph node tissue samples from chronically infected patients. Antiviral Therapy 15 (Suppl): A41.